Abstract
Magnetic fluid hyperthermia has been recently considered as a Renaissance of cancer treatment modality due to its remarkably low side effects and high treatment efficacy compared to conventional chemotheraphy or radiotheraphy. However, insufficient AC induction heating power at a biological safe range of AC magnetic field (Happl·fappl < 3.0–5.0 × 109 A m−1 s−1), and highly required biocompatibility of superparamagnetic nanoparticle (SPNP) hyperthermia agents are still remained as critical challenges for successful clinical hyperthermia applications. Here, newly developed highly biocompatible magnesium shallow doped γ-Fe2O3 (Mg0.13-γFe2O3) SPNPs with exceptionally high intrinsic loss power (ILP) in a range of 14 nH m2 kg−1, which is an ≈100 times higher than that of commercial Fe3O4 (Feridex, ILP = 0.15 nH m2 kg−1) at Happl·fappl = 1.23 × 109 A m−1 s−1 are reported. The significantly enhanced heat induction characteristics of Mg0.13-γFe2O3 are primarily due to the dramatically enhanced out-of-phase magnetic susceptibility and magnetically tailored AC/DC magnetic softness resulted from the systematically controlled Mg2+ cations distribution and concentrations in octahedral site Fe vacancies of γ-Fe2O3 instead of well-known Fe3O4 SPNPs. In vitro and in vivo magnetic hyperthermia studies using Mg0.13-γFe2O3 nanofluids are conducted to estimate bioavailability and biofeasibility. Mg0.13-γFe2O3 nanofluids show promising hyperthermia effects to completely kill the tumors.
Magnesium-doped γ-Fe2O3 (Mg0.13-γFe2O3) superparamagnetic nanoparticles with exceptionally high intrinsic loss power of 14 nH m2 kg−1 which is ≈100 times higher than that of commercial Fe3O4 at a physiologically safe range of AC magnetic field (Happl·fappl = 1.23 × 109 A m−1 s−1) are developed. The hyperthermia effect using Mg0.13-γFe2O3 nanofluids is revealed to be promising for completely killing tumors.
http://ift.tt/2z2revx
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.